| Host |
Monospecific Mouse |
| Klon |
ZM29 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liver. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human CD163 fragment (around aa 43-196) |
| Lokalisation |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
0.5 ml |
Concentrate |
CE/IVD |
Z2361MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM29 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Liver. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human CD163 fragment (around aa 43-196) |
| Lokalisation |
Cytoplasm and Cell membrane |
CD163
|
Zeta Corporation |
ZM29 |
0.1 ml |
Concentrate |
CE/IVD |
Z2361MT |
-
|
| Host |
Mouse |
| Klon |
BRIC111 |
| Format |
Purified |
| Methode |
F |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human Tn red blood cells |
CD175
|
Zytomed Systems GmbH |
BRIC111 |
200 µg |
Purified |
RUO |
603-1631 |
-
|
| Host |
Mouse |
| Klon |
ZM360 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
| Lokalisation |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
1 ml |
Concentrate |
CE/IVD |
Z2736ML |
-
|
| Host |
Mouse |
| Klon |
ZM360 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
| Lokalisation |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
7 ml |
Concentrate |
CE/IVD |
Z2736MP |
-
|
| Host |
Mouse |
| Klon |
ZM360 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
| Lokalisation |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
0.5 ml |
Concentrate |
CE/IVD |
Z2736MS |
-
|
| Host |
Mouse |
| Klon |
ZM360 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant fragment (around aa1006-1130) of human LY75 protein |
| Lokalisation |
Cytoplasm |
CD205
|
Zeta Corporation |
ZM360 |
0.1 ml |
Concentrate |
CE/IVD |
Z2736MT |
-
|
| Host |
Mouse |
| Klon |
DX11 |
| Format |
Purified |
| Methode |
IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1)
|
Zytomed Systems GmbH |
DX11 |
200 µg |
Purified |
RUO |
603-1726 |
-
|
| Host |
Mouse |
| Klon |
DX11 |
| Format |
Purified |
| Methode |
IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1)
|
Zytomed Systems GmbH |
DX11 |
100 µg |
Purified |
RUO |
603-1728 |
-
|
| Host |
Mouse |
| Klon |
DX11 |
| Format |
Purified |
| Methode |
IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1) (Azide Free)
|
Zytomed Systems GmbH |
DX11 |
1 mg |
Purified |
RUO |
603-1732F |
-
|
| Host |
Mouse |
| Klon |
DX11 |
| Format |
Purified |
| Methode |
IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1) (Low Endotoxin)
|
Zytomed Systems GmbH |
DX11 |
500 µg |
Purified |
RUO |
603-1727 |
-
|
| Host |
Mouse |
| Klon |
DX11 |
| Format |
Purified |
| Methode |
IP, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human cytotoxic T lymphocyte clone |
CD226 (DNAM1, DNAX accessory molecule 1) - Biotin
|
Zytomed Systems GmbH |
DX11 |
100 µg |
Purified |
RUO |
603-1729B |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Purified |
| Methode |
IHC(P), WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Mouse brain tissue |
| Verdünnung |
0.5 - 1 µg/ml (~ 1:1.000 - 1:2.000) |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A peptide corresponding to a 16 amino acid sequence from near the centre of Human CD273. |
CD273 (PD-L2)
|
Zytomed Systems GmbH |
polyclonal |
100 µg (100 µl) |
Purified |
RUO |
603-2393 |
-
|
| Host |
Rabbit |
| Klon |
SP98 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil, reactive lymph node |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD278 |
| Lokalisation |
Cell Membrane |
CD278
|
Zytomed Systems GmbH |
SP98 |
0.5 ml |
Concentrate |
RUO |
509-3982 |
-
|
| Host |
Rabbit |
| Klon |
SP98 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil, reactive lymph node |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to the C-terminus of human CD278 |
| Lokalisation |
Cell Membrane |
CD278
|
Zytomed Systems GmbH |
SP98 |
1 ml |
Concentrate |
RUO |
509-3984 |
-
|
| Host |
Mouse |
| Klon |
VU-ID9 |
| Format |
Purified |
| Methode |
F, P, WB, IP, FL |
| Vorbehandlung |
Trypsin |
| Positivkontrolle |
Large Bowel |
| Verdünnung |
1:200 (P) |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
HG9 cell line (small cell lung carcinoma) |
CD326
|
Zytomed Systems GmbH |
VU-ID9 |
200 µg |
Purified |
RUO |
603-2331 |
-
|
| Host |
Mouse |
| Klon |
DCS.120+DCS.121 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Nuclear Membrane |
CDC25A
|
Diagnostic Biosystems |
DCS.120+DCS.121 |
1 ml |
Concentrate |
CE/IVD |
MOB337 |
-
|
| Host |
Mouse |
| Klon |
DCS.120+DCS.121 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Nuclear Membrane |
CDC25A
|
Diagnostic Biosystems |
DCS.120+DCS.121 |
0.1 ml |
Concentrate |
CE/IVD |
MOB337-01 |
-
|
| Host |
Mouse |
| Klon |
DCS.120+DCS.121 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG2a |
| Lokalisation |
Nuclear Membrane |
CDC25A
|
Diagnostic Biosystems |
DCS.120+DCS.121 |
0.5 ml |
Concentrate |
CE/IVD |
MOB337-05 |
-
|
| Host |
Rabbit |
| Klon |
ZR394 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma, well-differentiated liposarcoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the N-terminal of human CDK4 protein |
| Lokalisation |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
1.0 ml |
Concentrate |
RUO |
Z2750RL-R |
-
|
| Host |
Rabbit |
| Klon |
ZR394 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma, well-differentiated liposarcoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the N- terminal of human CDK4 protein. |
| Lokalisation |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
7 ml |
Ready-to-use |
RUO |
Z2750RP-R |
-
|
| Host |
Rabbit |
| Klon |
ZR394 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma, well-differentiated liposarcoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the N-terminal of human CDK4 protein |
| Lokalisation |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
0.5 ml |
Concentrate |
RUO |
Z2750RS-R |
-
|
| Host |
Rabbit |
| Klon |
ZR394 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Urothelial carcinoma, well-differentiated liposarcomama. |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment corresponding to the N-terminal of human CDK4 protein. |
| Lokalisation |
Nuclear and Cytoplasm |
CDK4
|
Zeta Corporation |
ZR394 |
0.1 ml |
Concentrate |
RUO |
Z2750RT-R |
-
|
| Host |
Mouse |
| Klon |
DCS-156 |
| Format |
Concentrate |
| Methode |
F, P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Liposarcoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
Cdk4 (Cyclin dependant Kinase)
|
Zytomed Systems GmbH |
DCS-156 |
200 µl |
Concentrate |
RUO |
A03-61096 |
-
|
| Host |
Mouse |
| Klon |
DCS-31.2 |
| Format |
Concentrate |
| Methode |
F, P, WB, |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Liposarkoma |
| Verdünnung |
1:100 - 1:250 |
| Isotyp |
Mouse IgG1 |
Cdk4 (Cyclin dependent Kinase)
|
Zytomed Systems GmbH |
DCS-31.2 |
100 µg |
Concentrate |
RUO |
603-1840 |
-
|
| Host |
Mouse |
| Klon |
BC39 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3184A |
-
|
| Host |
Mouse |
| Klon |
BC39 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
1 ml |
Concentrate |
CE/IVD |
ACI3184C |
-
|
| Host |
Mouse |
| Klon |
BC39 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
6 ml |
Ready-to-use |
CE/IVD |
API3184AA |
-
|
| Host |
Mouse |
| Klon |
BC39 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Nucleus |
CDX-2
|
Biocare Medical |
BC39 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3184G |
-
|
| Host |
Mouse |
| Klon |
AMT28 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Lokalisation |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
AMT28 |
6 ml |
Ready-to-use |
CE/IVD |
PDM187 |
-
|
| Host |
Rabbit |
| Klon |
EP25 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon, Colon adenocarcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
1 ml |
Concentrate |
CE/IVD |
RMAB059 |
-
|
| Host |
Rabbit |
| Klon |
EP25 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon, Colon adenocarcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB059-01 |
-
|
| Host |
Rabbit |
| Klon |
EP25 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon, Colon adenocarcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB059-05 |
-
|
| Host |
Rabbit |
| Klon |
EP25 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon, Colon adenocarcinoma |
| Isotyp |
Rabbit IgG |
| Verdünnung |
A synthetic peptide corresponding to residues near the C-term of human CDX-2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Diagnostic Biosystems |
EP25 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD059 |
-
|
| Host |
Rabbit |
| Klon |
ZR215 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal colon or colon adenocarcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 |
| Verdünnung |
Recombinant human full-length CDX2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
1.0 ml |
Concentrate |
CE/IVD |
Z2494RL |
-
|
| Host |
Rabbit |
| Klon |
ZR215 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal colon or colon adenocarcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Recombinant human full-length CDX2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
7 ml |
Ready-to-use |
CE/IVD |
Z2494RP |
-
|
| Host |
Rabbit |
| Klon |
ZR215 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal colon or colon adenocarcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 |
| Verdünnung |
Recombinant human full-length CDX2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
0.5 ml |
Concentrate |
CE/IVD |
Z2494RS |
-
|
| Host |
Rabbit |
| Klon |
ZR215 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal colon or colon adenocarcinoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 |
| Verdünnung |
Recombinant human full-length CDX2 protein |
| Lokalisation |
Nucleus |
CDX-2
|
Zeta Corporation |
ZR215 |
0.1 ml |
Concentrate |
CE/IVD |
Z2494RT |
-
|
| Host |
Mouse + Rabbit |
| Klon |
CDX2-88 + EP86 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Normal colon or colon cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 + Rabbit IgG |
| Lokalisation |
Nuclear and cytoplasmic/cell membrane |
CDX-2 (M) + CDH17 (RM)
|
Biocare Medical |
CDX2-88 + EP86 |
6 ml |
Ready-to-use |
CE/IVD |
API3135DSAA |
-
|
| Host |
Mouse+Rabbit |
| Klon |
CDX2-88 + BC1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer, breast cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 + Rabbit IgG |
| Lokalisation |
Nuclear and cytoplasmic |
CDX-2 + Cytokeratin 7
|
Biocare Medical |
CDX2-88 + BC1 |
6 ml |
Ready-to-use |
CE/IVD |
PM367DSAA |
-
|
| Host |
Mouse+Rabbit |
| Klon |
CDX2-88 + BC1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer, breast cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 + Rabbit IgG |
| Lokalisation |
Nuclear and cytoplasmic |
CDX-2 + Cytokeratin 7
|
Biocare Medical |
CDX2-88 + BC1 |
25 ml |
Ready-to-use |
CE/IVD |
PM367DSH |
-
|
| Host |
Mouse |
| Klon |
CEA31 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
1.0 ml |
Concentrate |
CE/IVD |
Z2100ML |
-
|
| Host |
Mouse |
| Klon |
CEA31 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
7 ml |
Ready-to-use |
CE/IVD |
Z2100MP |
-
|
| Host |
Mouse |
| Klon |
CEA31 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
0.5 ml |
Concentrate |
CE/IVD |
Z2100MS |
-
|
| Host |
Mouse |
| Klon |
CEA31 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-M
|
Zeta Corporation |
CEA31 |
0.1 ml |
Concentrate |
CE/IVD |
Z2100MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
1.0 ml |
Concentrate |
CE/IVD |
Z2565RL |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
7 ml |
Ready-to-use |
CE/IVD |
Z2565RP |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
Z2565RS |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Human colon carcinoma extract |
| Lokalisation |
Cytoplasm and luminal Cell membrane |
CEA-P
|
Zeta Corporation |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
Z2565RT |
-
|
| Host |
Rabbit |
| Klon |
DBRRM2.85 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:100-1:200 |
| Isotyp |
IgG kappa |
| Verdünnung |
Recombinant human CEA protein fragment |
| Lokalisation |
Cell Surface |
CEACAM5
|
Diagnostic Biosystems |
DBRRM2.85 |
1 ml |
Concentrate |
Übergangsfrist |
RMAB118R |
-
|